143 related articles for article (PubMed ID: 9021740)
21. Antisense and nonantisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy.
Kim R; Emi M; Matsuura K; Tanabe K
Cancer Gene Ther; 2007 Jan; 14(1):1-11. PubMed ID: 17041564
[TBL] [Abstract][Full Text] [Related]
22. [Gene therapy].
RodrÃguez-Fragoso L
Rev Invest Clin; 1997; 49(5):397-409. PubMed ID: 9527700
[TBL] [Abstract][Full Text] [Related]
23. Antisense oligonucleotides: towards clinical trials.
Agrawal S
Trends Biotechnol; 1996 Oct; 14(10):376-87. PubMed ID: 8987636
[TBL] [Abstract][Full Text] [Related]
24. Oligonucleotides as antivirals: dream or realistic perspective?
Van Aerschot A
Antiviral Res; 2006 Sep; 71(2-3):307-16. PubMed ID: 16621039
[TBL] [Abstract][Full Text] [Related]
25. Antisense approaches to immune modulation for transplant and autoimmune diseases.
Mourich DV; Marshall NB
Curr Opin Pharmacol; 2005 Oct; 5(5):508-12. PubMed ID: 16087396
[TBL] [Abstract][Full Text] [Related]
26. Antisense oligonucleotides as therapeutic agents.
Alama A; Barbieri F; Cagnoli M; Schettini G
Pharmacol Res; 1997 Sep; 36(3):171-8. PubMed ID: 9367660
[TBL] [Abstract][Full Text] [Related]
27. [Prospects for antisense therapy of human leukemias].
Maekawa T
Hum Cell; 1996 Mar; 9(1):17-24. PubMed ID: 9183625
[TBL] [Abstract][Full Text] [Related]
28. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
29. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
30. Antisense therapy in cancer.
Pawlak W; Zolnierek J; Sarosiek T; Szczylik C
Cancer Treat Rev; 2000 Oct; 26(5):333-50. PubMed ID: 11006135
[TBL] [Abstract][Full Text] [Related]
31. RNAi: a novel antisense technology and its therapeutic potential.
Dallas A; Vlassov AV
Med Sci Monit; 2006 Apr; 12(4):RA67-74. PubMed ID: 16572063
[TBL] [Abstract][Full Text] [Related]
32. Antisense molecules for targeted cancer therapy.
Wacheck V; Zangemeister-Wittke U
Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
[TBL] [Abstract][Full Text] [Related]
33. Antisense oligonucleotides as therapeutic agents.
Galderisi U; Cascino A; Giordano A
J Cell Physiol; 1999 Nov; 181(2):251-7. PubMed ID: 10497304
[TBL] [Abstract][Full Text] [Related]
34. Technology evaluation: ISIS-2503, Isis Pharmaceuticals.
Morse MA
Curr Opin Mol Ther; 2001 Dec; 3(6):589-94. PubMed ID: 11804274
[TBL] [Abstract][Full Text] [Related]
35. Antisense therapy for cancer.
Gleave ME; Monia BP
Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
[TBL] [Abstract][Full Text] [Related]
36. A potential role for antisense oligonucleotide analogues in the development of oncogene targeted cancer chemotherapy.
Tidd DM
Anticancer Res; 1990; 10(5A):1169-82. PubMed ID: 2241097
[TBL] [Abstract][Full Text] [Related]
37. Targeting tumor cell resistance to apoptosis induction with antisense oligonucleotides: progress and therapeutic potential.
Olie RA; Zangemeister-Wittke U
Drug Resist Updat; 2001 Feb; 4(1):9-15. PubMed ID: 11512155
[TBL] [Abstract][Full Text] [Related]
38. Technology evaluation: AVI-4126, AVI BioPharma.
Stephens AC
Curr Opin Mol Ther; 2004 Oct; 6(5):551-8. PubMed ID: 15537057
[TBL] [Abstract][Full Text] [Related]
39. Antisense treatments for biothreat agents.
Warfield KL; Panchal RG; Aman MJ; Bavari S
Curr Opin Mol Ther; 2006 Apr; 8(2):93-103. PubMed ID: 16610760
[TBL] [Abstract][Full Text] [Related]
40. Antisense oligonucleotides in cancer.
Castanotto D; Stein CA
Curr Opin Oncol; 2014 Nov; 26(6):584-9. PubMed ID: 25188471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]